ArticlePloS one2016
Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Identifying best modelling practices for tobacco control policy simulations: a systematic review and a novel quality assessment framework.Tobacco control · 2023Pooled it
- Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.Health technology assessment (Winchester, England) · 2023Pooled it
- Markov-model cost-effectiveness evaluation of a cessation programme when tobacco policies are comprehensive.BMJ open · 2026Article
- Smoking and social inequalities in France, 20 years of evolution: A secondary dataset analysis of health barometers.Tobacco induced diseases · 2026Article
- Economic evaluation of the recent French tobacco control policy: a model-based approach.Tobacco control · 2025Article
- Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021.BMC public health · 2025Article
- Switching from Cigarettes to Heated Tobacco Products in Japan-Potential Impact on Health Outcomes and Associated Health Care Costs.Healthcare (Basel, Switzerland) · 2024Article
- Providing Free Access to Smoking Cessation Medications: Does It Have an Impact on the Treatment Adherence and Success of Smoking Cessation?Turkish thoracic journal · 2021Article
- Cost-effectiveness analysis of text messaging to support health advice for smoking cessation.Cost effectiveness and resource allocation : C/E · 2021Article
- Comparative assessment of outcomes of smoking cessation therapies and role of free medications in successful long-term abstinence.Tobacco induced diseases · 2021Article
- Private and social time preference for health outcomes: A general population survey in Iran.PloS one · 2019Article
- How does reimbursement status affect smoking cessation interventions? A real-life experience from the Eastern Black Sea region of Turkey.Tobacco induced diseases · 2019Article
- Social climate on tobacco control in an advanced tobacco control country: A population-based study in Finland.Nordisk alkohol- & narkotikatidskrift : NAT · 2018Article
- Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation.Addiction (Abingdon, England) · 2018Article
- Experiences of COPD patients with existing smoking cessation programs and their preferences for improvement - a qualitative analysis.Tobacco induced diseases · 2016Article
- Effect of Funding Medications for Nicotine Dependence on Tobacco Control: A Narrative Review.Open respiratory archivesReview
- Prevalence, Knowledge and Perceptions of Smoking and Tobacco Products and Vape Among SEPAR Members.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextIn France more than 70,000 deaths from diseases related to smoking are recorded each year, and since 2005 prevalence of tobacco has increased. Providing free access to smoking cessation treatment would reduce this burden. The aim of our study was to estimate the incremental cost-effectiveness ratios (ICER) of providing free access to cessation treatment taking into account the cost offsets associated with the reduction of the three main diseases related to smoking: lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). To measure the financial impact of such a measure we also conducted a probabilistic budget impact analysis. METHODS AND
findingsWe performed a cost-effectiveness analysis using a Markov state-transition model that compared free access to cessation treatment to the existing coverage of €50 provided by the French statutory health insurance, taking into account the cost offsets among current French smokers aged 15-75 years. Our results were expressed by the incremental cost-effectiveness ratio in 2009 Euros per life year gained (LYG) at the lifetime horizon. We estimated a base case scenario and carried out a Monte Carlo sensitivity analysis to account for uncertainty. Assuming a participation rate of 7.3%, the ICER value for free access to cessation treatment was €3,868 per LYG in the base case. The variation of parameters provided a range of ICER values from -€736 to €15,715 per LYG. In 99% of cases, the ICER for full coverage was lower than €11,187 per LYG. The probabilistic budget impact analysis showed that the potential cost saving for lung cancer, COPD and CVD ranges from €15 million to €215 million at the five-year horizon for an initial cessation treatment cost of €125 million to €421 million.
conclusionThe results suggest that providing medical support to smokers in their attempts to quit is very cost-effective and may even result in cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.